<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26750">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01920815</url>
  </required_header>
  <id_info>
    <org_study_id>1R34HL115032-01A1--BAV</org_study_id>
    <secondary_id>OHSU IRB 8330</secondary_id>
    <nct_id>NCT01920815</nct_id>
  </id_info>
  <brief_title>Bicuspid Valve Aortopathy Feasibility Study</brief_title>
  <official_title>Bicuspid Valve Aortopathy: Feasibility of a Comparative Effectiveness Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Penn State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In order to determine the effectiveness of medical therapy options to prevent enlargement of
      the aorta in patients with a bicuspid aortic valve, a randomized study will be planned.
      This feasibility study will gather accurate data on number needed to screen, changes in
      medication use over time, and variance of the intended study endpoint.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will consider all patients with a bicuspid aortic valve and 1) determine the
      number of patients needed to be screened for a clinical trial, based on patient eligibility
      percentages applying specific inclusion and exclusion criteria, 2) for those meeting these
      criteria, follow changes in and compliance with medical therapy over two years, and 3) in a
      limited subset of eligible patients, perform MRI at baseline and after 2 years to measure
      the change in aortic area over time.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>Change in aortic area measured by MRI</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients will have a baseline and follow up MRI per a specific protocol to measure area of the ascending thoracic aorta.  All measurements will be performed by a core imaging lab</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical events involving the aorta, including change in medical therapy</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will observe for any major clinical events over time such as need for surgery, as well as changes in medical therapy over time.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Bicuspid Aortic Valve</condition>
  <arm_group>
    <arm_group_label>Beta blocker therapy</arm_group_label>
    <description>Cohort will consist of those actively taking any beta blocker medication.  Observation only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARB therapy</arm_group_label>
    <description>Cohort will consist of those actively taking any angiotensin receptor blocker medication.  Observation only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No therapy</arm_group_label>
    <description>Cohort will consist of those not taking either beta blocker nor angiotensin receptor blocker.  Observation only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No interventions</intervention_name>
    <arm_group_label>Beta blocker therapy</arm_group_label>
    <arm_group_label>ARB therapy</arm_group_label>
    <arm_group_label>No therapy</arm_group_label>
    <other_name>Observation only</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a bicuspid aortic valve.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Bicuspid aortic valve

          -  Aortic measurement of 35 - 49 mm on prior imaging study

        Exclusion Criteria:

          -  Prior aortic valve or thoracic aortic surgery

          -  Prior aortic dissection

          -  Other condition associated with enlarged aorta including Coarctation, Marfans, Turner
             syndrome, Loeys-Dietz, etc.

          -  Severe aortic stenosis or regurgitation

          -  Contraindication to MRI such as claustrophobia or implanted pacer/defibrillator

          -  Anticipated pregnancy, surgery, or move outside the area within 2 years
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aynun Naher</last_name>
    <phone>503-494-8750</phone>
    <email>nahera@ohsu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Craig Broberg, MD</last_name>
    <phone>503-494-7400</phone>
    <email>brobergc@ohsu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamil Aboulhosn, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Kay, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Book, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aynun Naher</last_name>
      <phone>503-494-8750</phone>
      <email>nahera@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Craig Broberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Ting, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wayne Franklin, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 9, 2014</lastchanged_date>
  <firstreceived_date>August 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Craig Broberg</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
